Regis Technologies, Inc.

Regis Technologies, Inc. is a U. S. -based company specializing in the development and manufacturing of active pharmaceutical ingredients (APIs) and providing contract development and manufacturing organization (CDMO) services to the pharmaceutical industry.

Founded in 1956 and headquartered in Morton Grove, US, Regis Technologies focuses on the pharmaceutical sector, engaging in the custom development of APIs and related services. The company has undergone strategic pivots to enhance its service offerings and expand its market presence. It has secured 1 investment deal as of July 30, 2025, when it was acquired by Esteve Healthcare, S. L.

, a portfolio company of Lubea. Financial terms of the transaction were not disclosed. Regis Technologies specializes in the development and manufacturing of active pharmaceutical ingredients (APIs) and offers a comprehensive range of contract development and manufacturing organization (CDMO) services. Their primary product offerings include custom API development, analytical development, and cGMP (current Good Manufacturing Practice) manufacturing, serving pharmaceutical innovators who require reliable and efficient solutions for small molecule drug development.

The company also provides chromatography products, such as chiral and achiral HPLC and SFC columns, which are essential for separating and analyzing complex chemical mixtures. Regis Technologies targets a diverse client base that includes pharmaceutical companies, biotechnology firms, and research institutions, primarily in North America and Europe. By addressing the intricate challenges in molecule development, Regis plays a vital role in helping clients bring innovative therapies to market. Regis Technologies generates revenue through direct business transactions with pharmaceutical and biotechnology companies, primarily structured as B2B relationships.

Clients engage the firm for customized API manufacturing and chromatography products, often entering into contracts that specify project scopes, timelines, and deliverables. Revenue is driven by the fulfillment of these contracts and can involve milestone payments tied to production stages, as well as bulk orders of chromatography columns and specialty reagents. The pricing structure for products and services is aligned with industry standards, reflecting the value of the high-quality materials and expertise provided by Regis. Their flagship offerings in custom API development and chromatography columns form the core of their revenue-generating activities, contributing to their reputation as a trusted partner in the pharmaceutical development landscape.

In July 2025, Esteve Healthcare, S. L. acquired Regis Technologies, Inc. , aiming to strengthen its market presence and expand its services.

This acquisition will support Regis in launching upcoming products and technologies. The company plans to enter new markets within North America and Europe, which will be essential for its growth strategy. The recent acquisition will provide the necessary resources to enhance these initiatives.